Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ANVSNYSEAMERICAN:APHBNASDAQ:EVAXNASDAQ:GANXCVE:MPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$18.08+32.9%$10.64$5.42▼$22.49$199.06M1.59278,709 shs1.06 million shsAPHBAmpliphi Biosciences$2.76+9.1%$0.00$0.15▼$1.37$92.37MN/A842,200 shs9,511 shsEVAXEvaxion Biotech A/S$4.18+1.5%$3.57$2.82▼$18.50$21.82M-0.02531,819 shs25,104 shsGANXGain Therapeutics$3.03-1.3%$3.97$2.00▼$5.65$49.15M0.43154,365 shs179,297 shsMPHMedicureC$1.00-2.0%C$1.13C$0.99▼C$1.80C$10.25M1.014,487 shs4,900 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+6.58%+37.65%+14.29%+37.24%-8.48%EVAXEvaxion Biotech A/S-0.24%-2.37%+31.63%-44.17%-67.81%GANXGain Therapeutics-3.76%-2.54%-19.21%-18.13%-40.27%MPHMedicure-6.42%-0.97%-15.00%-12.07%-22.14%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio2.0411 of 5 stars3.42.00.00.02.81.70.6APHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/S1.7335 of 5 stars3.53.00.00.00.61.70.6GANXGain Therapeutics3.0876 of 5 stars3.53.00.00.03.82.50.6MPHMedicureN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio2.75Moderate Buy$27.7553.48% UpsideAPHBAmpliphi BiosciencesN/AN/AN/AN/AEVAXEvaxion Biotech A/S3.00Buy$11.00163.16% UpsideGANXGain Therapeutics3.00Buy$8.50180.53% UpsideMPHMedicureN/AN/AN/AN/ACurrent Analyst RatingsLatest ANVS, APHB, MPH, GANX, and EVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/23/2024GANXGain TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/3/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.004/2/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.004/2/2024EVAXEvaxion Biotech A/SLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.004/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/20/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.002/12/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/S$70K311.71N/AN/A($1.17) per share-3.57GANXGain Therapeutics$50K982.93N/AN/A$0.97 per share3.12MPHMedicureC$22.94M0.45C$0.40 per share2.49C$2.10 per share0.48Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$6.22N/AN/AN/AN/A-446.06%-257.97%5/9/2024 (Estimated)APHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AEVAXEvaxion Biotech A/S-$22.12M-$6.76N/A32.15N/AN/A-451.63%-149.27%5/29/2024 (Estimated)GANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)MPHMedicureC$1.08MC$0.0911.11∞N/A4.71%5.04%2.49%5/24/2024 (Estimated)Latest ANVS, APHB, MPH, GANX, and EVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2024Q4 2023MPHMedicureN/A-C$0.14-C$0.14-C$0.14N/AC$5.07 million3/29/2024Q4 2023ANVSAnnovis BioN/A-$1.09-$1.09$0.15N/AN/A3/27/2024Q4 2023EVAXEvaxion Biotech A/SN/A-$0.16-$0.16-$0.16N/A$0.07 million3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.392.39APHBAmpliphi BiosciencesN/AN/AN/AEVAXEvaxion Biotech A/SN/A1.181.18GANXGain Therapeutics0.043.593.59MPHMedicure2.862.281.29OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%APHBAmpliphi BiosciencesN/AEVAXEvaxion Biotech A/S11.04%GANXGain Therapeutics11.97%MPHMedicure23.10%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio38.30%APHBAmpliphi BiosciencesN/AEVAXEvaxion Biotech A/S41.64%GANXGain Therapeutics11.00%MPHMedicure26.99%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio611.01 million6.79 millionOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableEVAXEvaxion Biotech A/S635.22 million3.04 millionOptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableMPHMedicureN/A10.25 millionN/ANot OptionableANVS, APHB, MPH, GANX, and EVAX HeadlinesSourceHeadlineCluj-Napoca, Romania - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 24 at 4:02 PMMedicure, Inc.: Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiencyfinanznachrichten.de - April 23 at 7:02 PMLiverpool, United Kingdom - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 22 at 7:18 AMSofia, Bulgaria - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 21 at 8:46 AMDallas, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 19 at 9:27 AMPrescott, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 18 at 1:03 PMPortland, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 11 at 7:15 PMOttawa, Canada - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 11 at 9:15 AMFastest Cars In The World Rankedtopspeed.com - April 10 at 7:38 PMOlathe, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 8 at 8:18 PMSpringfield, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 7 at 5:37 PMParsippany, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 2 at 3:25 AMFrankfort, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 1 at 9:33 AMMississippi, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - April 1 at 1:25 AMMPH Master of Public Health (on campus)manchester.ac.uk - March 28 at 11:48 AMCharing - Weather warnings issuedbbc.com - March 21 at 2:49 PMMesquite, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - March 17 at 1:10 AMWilliams, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - March 15 at 1:31 PMPortishead - Weather warnings issuedbbc.com - March 2 at 12:14 AM2026 Tesla Roadstercaranddriver.com - February 29 at 8:36 PMZenjan, Iran - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - February 22 at 10:16 AMChelmsford - Weather warnings issuedbbc.com - February 22 at 10:16 AMBucharest, Romania - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - February 18 at 10:07 AMRedruth - Weather warnings issuedbbc.com - February 15 at 6:54 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnnovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Ampliphi BiosciencesNYSEAMERICAN:APHBAmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Evaxion Biotech A/SNASDAQ:EVAXEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.MedicureCVE:MPHMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.